POSA61 Incremental Cost per Relapse Avoided of Ozanimod Compared with First-Line Disease-Modifying Therapies for Relapsing Forms of Multiple Sclerosis
Abstract
Authors
D Kantor T Pham O Patterson-Lomba E Swallow A Dua K Gupte-Singh